WCC BIOMEDICAL

WCC BIOMEDICAL (WCC) was established in 2014. It is a leading company that provides advanced biomedical products in the world. On the current project, we developed a precise and advanced platform called WINMAPᵀᴹ that could produce customized microneedle patches (MNPs) or also known as microarray patches (MAPs) for our clients with high quality consistently.

Vision

A novel, effective and painless transdermal drug delivery system (TDDS) would be a blessing to all the patients in the world, microneedle patch has the great potential to meet that goal; WCC is committed to be a leader on making MAP.

Mission

Currently, microneedle patch can be applied in four areas, i.e. cosmetic applications, drugs, vaccines and monitoring systems. WCC has been engaged and developed specific products in these four areas.

About Our Founder and Chairman

Dr. Ta-Jo Liu (劉大佼), the founder of WCC BIOMEDICAL, is an exceptional individual with extensive professional and academic experience in the field of coatings. He has held notable positions such as a senior research scientist at Kodak Co. (USA) and as a professor and chairman of the Chemical Engineering Department at National Tsing Hua University. In 1998, he established the Formosa Advanced Coating Co., Inc., solidifying his reputation as a leading coating expert in Asia. Dr. Liu’s contributions have been internationally recognized, including his role as the vice president of the International Society of Coating Science and Technology (ISCST) for two terms and his prestigious achievement of the John Tallmadge Award in 2008.

OUR STORY

  • 2024/02 Win Coat Corporation has officially changed to WCC BIOMEDICAL Co., Ltd.
2024
2023
  • Increase Capital by NTD 380 million.
  • 2023/05 Win Coat the only Taiwanese company that got invited to join MICRONEEDLE CONFERENCE 2023 at Seattle by PATH
  • 2023/06 Invited by Gates Foundation to join Shanghai Bioforum
  • 2023/08 obtain certification from the Bureau of Industry and Commerce with an innovative platform

  • Increased capital by NTD 210.88 million.
  • Completed animal study for vaccine microneedle patches.
  • Participated in the Ministry of Economic Affairs' T-Beauty humid and hot climate industry chain project.
  • Signed an exclusive distributor contract with a Japanese cosmetics manufacturer in the Asia-Pacific region.
2022
2021
  • Signed a contract for the development of vaccine microneedle patches with a listed vaccine company.
  • Completed the development of three self-developed cosmetics products.
  • Completed clinical trials for three cosmetics products.
  • Obtained invention patents in the United States, Europe, and other countries.
  • In January 2021, applied for European Patent No. EP19209380.5 "Base Composition For Microneedle Patch And Microneedle Patch Comprising The Same."
  • In April 2021, obtained Japanese Patent No. 6868913 "マイクロニードルパッチ用のベース組成物及びこのベース組成物を含むマイクロニードルパッチ"
  • In May 2021, Win Coat was selected to join the Japan External Trade Organization (JETRO).
  • Win Coat increased capital by NTD 128.8 million.
  • Win Coat obtained cosmetics GMP and ISO22716 certification.
  • Win Coat completed the SBIR enterovirus vaccine microneedle patch development project.
  • First ODM product launched.
  • In January, Win Coat was the only Taiwanese company invited to participate in the PATH Microneedle Patch International Conference held by the Bill & Melinda Gates Foundation in Germany.
  • In October, Win Coat obtained US Patent No. US10793701B1 "Base Composition For Microneedle Patch And Microneedle Patch Comprising The Same."
  • In December, Win Coat successfully completed the turn-key project for mass production of microarray patches with a listed pharmaceutical company.
2020
2019
  • In April, Win Coat was invited to participate in the startup company matchmaking event Morning Pitch.
  • In April, successfully developed cosmetics anti-wrinkle eye mask patches.
  • In April, Win Coat selected as one of the four featured companies on the Gretai Securities Market's startup board, published in the Commercial Times on April 24.
  • In May, Win Coat selected as a biotechnology and medical company in the Ministry of Science and Technology's TTA Prototype Program Asia Silicon Valley Innovation Entrepreneurship Linkage Project.
  • In January, Win Coat moved into the Hsinchu Science Park.
  • In May, Win Coat received the Hsinchu Science Park's "Cross-industry Integration Biomedical Leap Project" to develop insulin-containing microneedle patches.
  • In June, Win Coat received grants from the Ministry of Science and Technology to jointly execute the project "Preparation of Biodegradable High Polymer Materials, Processes, and Product Development Based on Waste Glycerol" with National Tsing Hua University.
  • In July, Win Coat obtained ROC Patent No. I629073 for "Method of Producing Microneedle Patches."
  • Win Coat successfully developed cosmetics patches for lightening pigmentation in August.
  • In September, Win Coat obtained ROC Patent No. I633901 for "Method of Producing Cosmetics Microneedle Patches."
2018

Management Team

The management team led by Dr. Liu include 4 PhDs that have comprehensive knowledge and practical experience with several experience as managers in mass production field and business administration.

Technical Team

Over 70% of the team members are MS or PhD graduates in the areas of biomaterials, medical engineering, rheology and precision coating.

Business Area

  • ODM : Production and WCC's own MAP design
  • OEM : MAP specification and design according to customer need; WCC will produce and deliver products to customer
  • TURN-KEY SOLUTION: Technology transfer of MAP production technology to clients.

Core Technology

WINMAPTM Platform

  • Efficient Screening
  • Precision Processing
  • Automatic Mass Production

PATENT GROUP AND FACTORY QUALIFICATION

(1) Patents

(2) Certificates

(3) Industrial Services